⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555977 | 1.00 | — | — | |
| SCHEMBL10231631 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL489429 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL18138400 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL4177753 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL489428 | 0.96 | — | — | |
| Methyl Alcohol SCHEMBL17048302 | 0.92 | — | — | |
| SCHEMBL11839733 | 0.83 | — | — | |
| SCHEMBL489083 | 0.81 | — | — | |
| SCHEMBL75737 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465643-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250319187-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12409225-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12403196-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255964-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-14 | — | — | US | disclosed |
| US-20250242029-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250195662-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20250186590-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| US-12280113-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-04-22 | — | — | US | disclosed |
| US-7790884-B2 | Acylaminopiperidine compound | ASTELLAS PHARMA INC. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7790884-B2 | Acylaminopiperidine compound | ASTELLAS PHARMA INC. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131666-A1 | ACYLAMINOPIPERIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2000469-A9 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2000469-A2 | ACYLAMINOPIPERIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-7456194-B2 | Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20070037735-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |